Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia

Journal of Chemotherapy
Yanxun LiGeng Liu

Abstract

After decades of research, pancreatic cancer is still a devastating disease. The aim of this article was to assess the efficacy and safety of combination chemotherapy with gemcitabine (GEM) and S-1 (GS) therapy compared with GEM alone therapy in patients with locally advanced or metastatic pancreatic cancer. Relevant trials were identified by searching databases. Five trials were selected in this article. The indicators we used were overall response rate, disease control rate, 1-year survival rate and haematological toxicities. Meta-analysis of the pooled data demonstrated that the overall response rate (risk ratio, RR = 2.52, 95% confidence interval, CI: 1.85-3.42, P < 0.00001) and disease control rate (RR = 1.24, 95% CI: 1.12-1.37, P < 0.0001) were significantly different for the GS and GEM alone chemotherapies. Among the group of patients, 43.4% in the GS group and 31.4% in the GEM group survived more than a year. According to this, patients who use the GS regiment may have a better prognosis than the GEM regiment (RR = 1.62, 95% CI: 1.12-2.33, P = 0.04). The combination chemotherapy with GEM and S-1 group had higher haematological toxicities including neutropaenia (RR = 1.58, 95% CI: 1.17-2.14, P = 0.003) and thrombocytopae...Continue Reading

References

Nov 1, 1991·Statistics in Medicine·A Whitehead, J Whitehead
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Jan 19, 2000·The American Journal of Gastroenterology·R H HawesJ L Abbruzzese
Jun 5, 2003·Expert Opinion on Investigational Drugs·Matthew H Kulke
Mar 22, 2006·Best Practice & Research. Clinical Gastroenterology·Yu Jo Chua, David Cunningham
May 25, 2006·British Journal of Cancer·K NakamuraH Saisho
May 24, 2007·Cancer Chemotherapy and Pharmacology·Takuji OkusakaHiroshi Saito
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asma SultanaPaula Ghaneh
Nov 23, 2010·Digestive Diseases·Joachim Mössner
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick J LoehrerAl B Benson
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Sep 25, 2012·World Journal of Gastroenterology : WJG·Chen SunDe-Quan Wu
Apr 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hideki UenoMasao Tanaka
Aug 28, 2013·Cancer Chemotherapy and Pharmacology·Hunho SongDae Young Zang
Jun 14, 2014·Journal of Hepato-biliary-pancreatic Sciences·Hiroaki YanagimotoHiroyuki Isayama
Aug 1, 2014·Expert Opinion on Investigational Drugs·Amal H I Al Haddad, Thomas E Adrian
Dec 3, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L BergmannH Richly

❮ Previous
Next ❯

Citations

Jun 24, 2017·International Journal of Molecular Sciences·Aleksandra AdamskaMarco Falasca
Apr 14, 2016·Molecular and Clinical Oncology·Masaya MunekageKazuhiro Hanazaki
Aug 10, 2018·World Journal of Gastroenterology : WJG·Aleksandra Adamska, Marco Falasca
Feb 13, 2020·World Journal of Clinical Cases·Yang-Yang MaLi-Zhi Niu
Oct 14, 2018·Medicine·Hong ZhuHongfeng Gou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.